Anacor Pharma (ANAC) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anacor Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 3, 2015 7:00 AM ESTRecognized $21.1 million in total KERYDIN® revenue in the third quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 18.8% over the second quarter of 2015 Top-line results from the long-term safety study of crisaborole topical ointment, 2%, in patients with mild-to-moderate atopic dermatitis demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months Anacor expects to submit a New Drug Application for crisaborole topical ointment, 2%, to the U.S. Food and Drug Administration in the first quarter of... More
